AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
Bio-Techne (NASDAQ: TECH) and Nucleai presented SECOMBIT clinical-trial spatial biology data at SITC 2025 showing AI-integrated, high-plex imaging can identify predictive biomarkers in metastatic melanoma.
Researchers profiled 42 pre-treatment biopsies using the COMET platform and a 28-plex mIF panel; analyses linked specific immune cell locations and interactions to progression-free survival, overall survival, and clinical benefit across three treatment arms. The abstract was selected among the top 150 of ~1,200 submissions. Poster #528 and Bio-Techne booth #603 at SITC 2025 will display the data and new spatial biology products including ProximityScope and extended SPYRE portfolio.
Bio-Techne (NASDAQ: TECH) e Nucleai hanno presentato dati di biologia spaziale clinica SECOMBIT al SITC 2025, mostrando che l’imaging ad alto plex integrato con IA può identificare biomarcatori predittivi nel melanoma metastatico.
I ricercatori hanno profilo 42 biopsie pre-trattamento utilizzando la piattaforma COMET e un pannello mIF da 28 plex; le analisi hanno collegato posizioni e interazioni specifiche delle cellule immunitarie a progression-free survival, overall survival e beneficio clinico su tre braccia di trattamento. L’abstract è stato selezionato tra le top 150 di circa 1.200 lavori. Poster #528 e lo stand Bio-Techne #603 al SITC 2025 esibiranno i dati e i nuovi prodotti di biologia spaziale, tra cui ProximityScope e l’estesa portfolio SPYRE.
Bio-Techne (NASDAQ: TECH) y Nucleai presentaron datos de biología espacial clínica SECOMBIT en SITC 2025, que muestran que la imágenes de alto plex con IA integrada pueden identificar biomarcadores predictivos en melanoma metastásico.
Los investigadores analizaron 42 biopsias pretratamiento utilizando la plataforma COMET y un panel mIF de 28 plex; los análisis vincularon ubicaciones e interacciones específicas de células inmunes con supervivencia libre de progresión, supervivencia global y beneficio clínico a lo largo de tres brazos de tratamiento. El resumen fue seleccionado entre los top 150 de aproximadamente 1.200 presentaciones. El Póster #528 y el estand Bio-Techne #603 en SITC 2025 mostrarán los datos y nuevos productos de biología espacial, incluido ProximityScope y la cartera SPYRE ampliada.
Bio-Techne (NASDAQ: TECH) 와 Nucleai 는 SITC 2025에서 SECOMBIT 임상 시험의 공간 생물학 데이터를 발표했고, AI가 통합된 고plex 이미징이 전이성 흑색종에서 예측 바이오마커를 식별할 수 있음을 보였습니다.
연구진은 치료 전 42개 생검을 COMET 플랫폼과 28plex mIF 패널을 사용해 프로파일링했습니다; 분석은 특정 면역 세포의 위치와 상호작용이 무진행 생존(Progression-free survival), 전체 생존(Overall survival), 그리고 세 가지 치료군 전반의 임상적 이익과 연관되어 있음을 보여주었습니다. 초록은 약 1,200개 제출 중 상위 150 안에 선정되었습니다. SITC 2025의 포스터 #528 및 Bio-Techne 부스 #603에서 데이터와 ProximityScope 및 확장된 SPYRE 포트폴리오를 포함한 새로운 공간 생물학 제품들이 전시될 예정입니다.
Bio-Techne (NASDAQ: TECH) et Nucleai ont présenté des données cliniques de biologie spatiale SECOMBIT lors du SITC 2025, montrant qu’une imagerie à haut plex avec IA intégrée peut identifier des biomarqueurs prédictifs dans le mélanome métastatique.
Les chercheurs ont profilé 42 biopsies pré-traitement en utilisant la plateforme COMET et un panel mIF à 28 plex; les analyses ont relié des emplacements et des interactions spécifiques des cellules immunitaires à la survie sans progression, la survie globale et au bénéfice clinique sur trois bras de traitement. Le résumé a été sélectionné parmi les top 150 sur environ 1 200 soumissions. Le poster n°528 et le stand Bio-Techne n°603 au SITC 2025 présenteront les données et de nouveaux produits de biologie spatiale, dont ProximityScope et le portefeuille SPYRE étendu.
Bio-Techne (NASDAQ: TECH) und Nucleai präsentierten SECOMBIT-Daten zur räumlichen Biologie in der klinischen Praxis beim SITC 2025, die zeigen, dass KI-integrierte Hochplex-Imaging-Analysen prädiktive Biomarker beim metastasierenden Melanom identifizieren können.
Forscher profileten 42 Prä-Therapie-Biopsien mithilfe der COMET-Plattform und eines 28-Plex-mIF-Panels; Analysen stellten Verbindungen zwischen bestimmten Standorten und Interaktionen von Immunzellen zu fortschreitungsfreier Überlebenszeit, dem allgemeinen Überleben und dem klinischen Nutzen über drei Behandlungsarme hinweg her. Der Abstract wurde aus den ca. 1.200 Einreichungen unter den Top 150 ausgewählt. Poster Nr. 528 und Stand Nr. 603 von Bio-Techne auf dem SITC 2025 werden die Daten sowie neue räumliche Biologie-Produkte vorstellen, darunter ProximityScope und das erweiterte SPYRE-Portfolio.
Bio-Techne (NASDAQ: TECH) وNucleai قدما بيانات بيولوجيا مكانية سريرية SECOMBIT في SITC 2025، تُظهر أن التصوير عالي الـplex المدمج بالذكاء الاصطناعي يمكنه تحديد علامات حيوية تنبؤية في الورم الميلانيني النقيلي.
قام الباحثون بعمل ملفّ لـ 42 عينة سابقة العلاج باستخدام منصة COMET ولوحة mIF بـ 28 بلكس؛ ربطت التحليلات مواقع وتفاعلات خلايا مناعية محددة بـ البقاء بدون تقدم، والبقاء الإجمالي، والفائدة السريرية عبر ثلاثة أذرع علاجية. تم اختيار الملخص من بين أعلى 150 من نحو 1,200 مشاركة. ستعرض الملصق رقم 528 وركن Bio-Techne رقم 603 في SITC 2025 البيانات والمنتجات الجديدة لعلم الأحياء المكانية بما في ذلك ProximityScope ومحفظة SPYRE الموسعة.
- Study profiled 42 pre-treatment biopsies with COMET and 28-plex mIF
- Abstract selected among top 150 of ~1,200 SITC 2025 submissions
- AI multimodal analysis linked immune niches to PFS and OS
- Findings reported distinct marker–outcome links across three treatment arms
- Cohort size limited to 42 biopsies, constraining statistical power
Insights
Spatial-AI integration identified immune niches tied to clinical outcomes in melanoma, supporting biomarker utility for treatment selection.
Using the COMET™ platform and a 28-plex mIF panel, researchers profiled 42 pre-treatment biopsies and combined high-plex imaging, histopathology, and clinical outcomes with an AI multimodal system to map immune cell locations and interactions related to progression-free survival and overall survival.
The main dependencies include the limited sample size (42 biopsies) and the need for independent validation to confirm predictive value across larger cohorts and varied clinical settings. Results show correlations—such as PD-L1+ CD8 and ICOS+ CD4 associations in Arm A, PD-1+ CD8 interactions at the invasive margin in Arm B, and APC-T‑cell versus macrophage interaction patterns in Arm C—but do not report validation metrics or effect sizes here.
Watch for external validation, peer-reviewed publication of full statistics, and broader cohort replication over the next 12–36 months; presentation selection at the
- Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients.
- Bio-Techne's COMET™ platform and Nucleai's multimodal spatial operating system profiled 42 biopsies, revealing immune cell interactions linked to clinical outcomes.
- Study selected by the scientific committee as one of the top 150 abstracts from over 1,200 submissions at SITC 2025.
The study, conducted in collaboration with Professor Paolo Ascierto, Full Professor of Oncology at the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, showcases the significance of spatial biology in translational research by combining, for the first time, an immuno-oncology (IO) multiplex immunofluorescence (mIF) panel with advanced AI-driven multimodal biomarker analysis.
Study Overview
Using the COMET platform and a 28-plex mIF panel, researchers profiled 42 pre-treatment biopsies from patients with metastatic melanoma. Nucleai's multimodal spatial operating system integrated high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB).
Key Findings
-
Arm A (MAPKi → ICB): Immune activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells are linked to better outcomes.
-
Arm B (ICB → MAPKi): PD-1+ CD8 T-cells in the tumor invasive margin and their interactions with PD-L1+ CD4 T-cells correlated with improved survival.
- Arm C (MAPKi → ICB → MAPKi): APC-T-cell interactions in tumor margins associated with better outcomes; macrophage interactions in outer tumor microenvironment (TME) indicated poorer prognosis.
The study shows that where immune cells are located and how they interact within the tumor matters significantly for treatment success. By using AI and spatial biology to map these immune niches, researchers can better predict which patients will benefit from specific therapies moving toward more personalized and effective cancer treatment.
"This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology," said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne
"Our multimodal spatial operating system enables integration of high-plex imaging, data, and clinical information to identify predictive biomarkers in clinical settings," said Avi Veidman, CEO of Nucleai. "This collaboration shows how precision medicine products can become more accurate, explainable, and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone."
"The SECOMBIT trial is a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study," added Dr. Ascierto.
Availability at SITC 2025
Bio-Techne's full spatial biology portfolio—including the new ProximityScope™ assay and the extended SPYRE™ portfolio will be showcased at Booth #603 at SITC 2025. Visual data from the SECOMBIT study will also be presented in Poster # 528, alongside additional immuno-oncology research from Bio-Techne and its collaborators.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
About Nucleai
Nucleai is an AI-powered multimodal spatial biology company, transforming tissue imaging into actionable insights for drug development and diagnostics. Nucleai's multimodal spatial operating system integrates high-plex spatial proteomics, histopathology, and clinical data to identify predictive spatial biomarkers and power the development of next-generation precision medicine products. Nucleai partners with leading pharmaceutical, diagnostic, and academic institutions globally. Learn more at https://nucleai.ai/.
Media Contacts:
Bio-Techne
Corporate Communications -- media.relations@bio-techne.com
Investor Relations -- david.clair@bio-techne.com
Nucleai
Press – press@nucleai.ai
View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-powered-spatial-biology-workflow-from-bio-techne-and-nucleai-enables-predictive-biomarker-discovery-in-melanoma-patients-302604119.html
SOURCE Bio-Techne Corporation
FAQ
What did Bio-Techne (TECH) and Nucleai present from the SECOMBIT trial at SITC 2025?
Which biomarkers did the SECOMBIT study link to better outcomes for TECH at SITC 2025?
How many patient samples were profiled in the SECOMBIT study presented by TECH and Nucleai?
Where and how can investors view the SECOMBIT results from TECH presented at SITC 2025?
What clinical impact did the TECH and Nucleai analysis claim for melanoma treatment selection?
